Mersana Therapeutics Key Executives
This section highlights Mersana Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Mersana Therapeutics
(Showing 0 of )
Mersana Therapeutics Earnings
This section highlights Mersana Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-03 | $-0.16 | $-0.11 |
| Read Transcript | Q3 | 2024 | 2024-11-13 | $-0.18 | $-0.09 |
| Read Transcript | Q2 | 2024 | 2024-08-13 | $-0.18 | $-0.20 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.18 | $-0.16 |
| Read Transcript | Q4 | 2023 | 2024-02-28 | $-0.20 | $-0.16 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $-0.31 | $-0.35 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-0.41 | $-0.52 |
Financial Statements
Access annual & quarterly financial statements for Mersana Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $40.50M | $36.85M | $26.58M | $43.00K | $828.00K |
| Cost of Revenue | $1.63M | $148.27M | $927.00K | $132.01M | $67.04M |
| Gross Profit | $38.87M | $-111.41M | $25.65M | $-131.97M | $-66.21M |
| Gross Profit Ratio | 95.98% | -302.30% | 96.51% | -306906.98% | -7996.14% |
| Research and Development Expenses | $73.02M | $148.27M | $173.38M | $132.01M | $67.04M |
| General and Administrative Expenses | $40.81M | $59.54M | $56.96M | $36.89M | $21.90M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $40.81M | $59.54M | $56.96M | $36.89M | $21.90M |
| Other Expenses | $- | $- | $-445.00K | $-1.20M | $- |
| Operating Expenses | $113.83M | $36.85M | $230.35M | $168.90M | $88.94M |
| Cost and Expenses | $113.83M | $207.81M | $230.35M | $168.90M | $88.94M |
| Interest Income | $8.44M | $12.07M | $2.88M | $65.00K | $424.00K |
| Interest Expense | $3.87M | $4.07M | $3.33M | $1.27M | $359.00K |
| Depreciation and Amortization | $1.63M | $1.52M | $927.00K | $855.00K | $1.01M |
| EBITDA | $-63.27M | $-166.08M | $-199.96M | $-167.94M | $-86.68M |
| EBITDA Ratio | -156.24% | -450.63% | -752.26% | -390553.49% | -10468.12% |
| Operating Income | $-73.34M | $-170.96M | $-204.69M | $-169.71M | $-87.69M |
| Operating Income Ratio | -181.09% | -463.86% | -770.08% | -394681.40% | -10590.10% |
| Total Other Income Expenses Net | $4.56M | $-713.00K | $-445.00K | $-1.20M | $65.00K |
| Income Before Tax | $-68.77M | $-171.67M | $-204.21M | $-170.06M | $-88.05M |
| Income Before Tax Ratio | -169.82% | -465.80% | -768.26% | -395488.37% | -10633.45% |
| Income Tax Expense | $418.00K | $- | $3.33M | $-855.00K | $359.00K |
| Net Income | $-69.19M | $-171.67M | $-207.54M | $-169.21M | $-88.40M |
| Net Income Ratio | -170.86% | -465.80% | -780.78% | -393500.00% | -10676.81% |
| EPS | $-0.56 | $-1.48 | $-2.22 | $-2.40 | $-1.44 |
| EPS Diluted | $-0.56 | $-1.48 | $-2.22 | $-2.40 | $-1.44 |
| Weighted Average Shares Outstanding | 122.54M | 116.11M | 93.65M | 70.58M | 61.49M |
| Weighted Average Shares Outstanding Diluted | 122.54M | 116.11M | 93.65M | 70.58M | 61.49M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.36M | $12.60M | $2.29M | $9.24M | $10.70M | $7.70M | $10.65M | $7.80M | $14.69M | $5.57M | $4.28M | $2.04M | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $796.00K | $11.00K |
| Cost of Revenue | $400.00K | $- | $17.25M | $423.00K | $447.00K | $427.00K | $324.00K | $319.00K | $282.00K | $50.64M | $41.23M | $205.00K | $37.37M | $35.27M | $31.95M | $27.41M | $22.86M | $16.55M | $15.41M | $12.22M |
| Gross Profit | $15.96M | $12.60M | $-14.95M | $8.82M | $10.25M | $7.27M | $10.33M | $7.48M | $14.41M | $-45.07M | $-36.95M | $1.83M | $-37.36M | $-35.26M | $-31.94M | $-27.40M | $-22.85M | $-16.54M | $-14.62M | $-12.21M |
| Gross Profit Ratio | 97.56% | 100.00% | -652.07% | 95.42% | 95.82% | 94.45% | 96.96% | 95.91% | 98.08% | -808.65% | -862.44% | 89.93% | -339609.09% | -320581.82% | -290400.00% | -249127.27% | -207690.91% | -150318.18% | -1836.31% | -110981.82% |
| Research and Development Expenses | $22.29M | $14.80M | $17.25M | $18.69M | $21.50M | $30.53M | $48.97M | $47.27M | $45.71M | $50.64M | $41.23M | $35.81M | $37.37M | $35.27M | $31.95M | $27.41M | $22.86M | $16.55M | $15.41M | $12.22M |
| General and Administrative Expenses | $8.89M | $9.86M | $10.50M | $11.56M | $10.13M | $12.89M | $18.19M | $18.33M | $14.80M | $14.57M | $14.80M | $12.78M | $10.67M | $10.12M | $8.88M | $7.21M | $5.91M | $5.88M | $5.17M | $4.94M |
| Selling and Marketing Expenses | $- | $- | $- | $-423.00K | $-447.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $8.89M | $9.86M | $10.50M | $11.14M | $9.69M | $12.89M | $18.19M | $18.33M | $14.80M | $14.57M | $14.80M | $12.78M | $10.67M | $10.12M | $8.88M | $7.21M | $5.91M | $5.88M | $5.17M | $4.94M |
| Other Expenses | $- | $-12.07M | $- | $- | $-1.70M | $8.21M | $2.19M | $- | $902.00K | $-172.00K | $- | $- | $-952.00K | $- | $-86.00K | $- | $- | $-73.00K | $- | $- |
| Operating Expenses | $31.17M | $12.60M | $27.75M | $29.82M | $31.18M | $51.64M | $67.16M | $65.60M | $60.51M | $65.21M | $56.03M | $48.59M | $48.04M | $45.40M | $40.84M | $34.62M | $28.77M | $22.43M | $20.58M | $17.16M |
| Cost and Expenses | $31.17M | $12.60M | $27.75M | $30.25M | $31.63M | $51.64M | $67.16M | $65.60M | $60.51M | $65.21M | $56.03M | $48.59M | $48.04M | $45.40M | $40.84M | $34.62M | $28.77M | $22.43M | $20.58M | $17.16M |
| Interest Income | $1.60M | $1.97M | $2.17M | $2.70M | $2.93M | $3.30M | $3.22M | $2.62M | $1.87M | $708.00K | $291.00K | $18.00K | $29.00K | $15.00K | $9.00K | $12.00K | $10.00K | $19.00K | $89.00K | $306.00K |
| Interest Expense | $903.00K | $986.00K | $983.00K | $1.00M | $1.05M | $1.02M | $1.02M | $983.00K | $964.00K | $880.00K | $760.00K | $724.00K | $981.00K | $98.00K | $95.00K | $93.00K | $92.00K | $92.00K | $87.00K | $88.00K |
| Depreciation and Amortization | $400.00K | $402.00K | $403.00K | $423.00K | $447.00K | $427.00K | $324.00K | $319.00K | $282.00K | $213.00K | $227.00K | $205.00K | $211.00K | $212.00K | $206.00K | $226.00K | $260.00K | $256.00K | $246.00K | $248.00K |
| EBITDA | $-12.81M | $-11.67M | $-22.88M | $-17.88M | $-18.05M | $-40.21M | $-52.96M | $-54.86M | $-43.68M | $-58.72M | $-51.23M | $-46.33M | $-47.79M | $-45.16M | $-40.61M | $-34.37M | $-28.49M | $-22.14M | $-19.45M | $-16.59M |
| EBITDA Ratio | -78.32% | -92.61% | -997.91% | -193.41% | -168.67% | -522.37% | -497.07% | -703.17% | -297.37% | -1053.62% | -1195.89% | -2275.49% | -434463.64% | -410554.55% | -369200.00% | -312490.91% | -259018.18% | -201281.82% | -2443.84% | -150818.18% |
| Operating Income | $-14.81M | $-12.07M | $-25.45M | $-21.00M | $-20.93M | $-41.66M | $-54.31M | $-55.18M | $-46.11M | $-59.64M | $-51.75M | $-46.53M | $-48.00M | $-45.39M | $-40.83M | $-34.61M | $-28.76M | $-22.42M | $-19.79M | $-17.14M |
| Operating Income Ratio | -90.53% | -95.80% | -1110.12% | -227.16% | -195.57% | -541.13% | -509.73% | -707.25% | -313.92% | -1070.14% | -1207.98% | -2285.56% | -436381.82% | -412618.18% | -371154.55% | -314654.55% | -261454.55% | -203781.82% | -2485.93% | -155854.55% |
| Total Other Income Expenses Net | $694.00K | $986.00K | $1.19M | $1.70M | $1.38M | $-5.93M | $2.19M | $1.64M | $902.00K | $-172.00K | $-469.00K | $-706.00K | $-952.00K | $-83.00K | $-86.00K | $-81.00K | $-80.00K | $-73.00K | $2.00K | $218.00K |
| Income Before Tax | $-14.12M | $-11.08M | $-24.27M | $-19.31M | $-19.54M | $-41.66M | $-54.31M | $-56.16M | $-44.92M | $-59.81M | $-52.22M | $-47.26M | $-48.98M | $-45.47M | $-40.91M | $-34.69M | $-28.84M | $-22.49M | $-19.79M | $-16.93M |
| Income Before Tax Ratio | -86.28% | -87.97% | -1058.35% | -208.83% | -182.64% | -541.13% | -509.73% | -719.85% | -305.86% | -1073.23% | -1218.93% | -2321.12% | -445300.00% | -413372.73% | -371936.36% | -315390.91% | -262200.00% | -204445.45% | -2485.68% | -153872.73% |
| Income Tax Expense | $- | $418.00K | $- | $379.72K | $5.70M | $-6.36M | $-324.00K | $983.00K | $964.00K | $-213.00K | $291.00K | $724.00K | $981.00K | $15.00K | $-206.00K | $12.00K | $10.00K | $-256.00K | $89.00K | $306.00K |
| Net Income | $-14.12M | $-11.50M | $-24.27M | $-19.31M | $-19.54M | $-41.66M | $-54.31M | $-57.15M | $-45.89M | $-59.81M | $-52.22M | $-47.98M | $-48.98M | $-45.47M | $-40.91M | $-34.69M | $-28.84M | $-22.49M | $-19.79M | $-16.93M |
| Net Income Ratio | -86.28% | -91.29% | -1058.35% | -208.83% | -182.64% | -541.13% | -509.73% | -732.45% | -312.42% | -1073.23% | -1218.93% | -2356.68% | -445300.00% | -413372.73% | -371936.36% | -315390.91% | -262200.00% | -204445.45% | -2485.68% | -153872.73% |
| EPS | $-0.11 | $-0.09 | $-0.20 | $-0.16 | $-0.16 | $-0.35 | $-0.47 | $-0.53 | $-0.45 | $-0.61 | $-0.55 | $-0.60 | $-0.68 | $-0.63 | $-0.59 | $-0.50 | $-0.42 | $-0.33 | $-0.33 | $-0.35 |
| EPS Diluted | $-0.11 | $-0.09 | $-0.20 | $-0.16 | $-0.16 | $-0.35 | $-0.47 | $-0.53 | $-0.45 | $-0.61 | $-0.55 | $-0.60 | $-0.68 | $-0.63 | $-0.59 | $-0.50 | $-0.42 | $-0.33 | $-0.33 | $-0.35 |
| Weighted Average Shares Outstanding | 123.56M | 122.72M | 122.44M | 121.42M | 120.61M | 120.52M | 115.61M | 107.51M | 101.01M | 97.64M | 95.76M | 79.93M | 71.92M | 71.75M | 69.62M | 68.99M | 68.42M | 68.42M | 60.75M | 47.99M |
| Weighted Average Shares Outstanding Diluted | 123.56M | 122.72M | 122.44M | 121.42M | 120.61M | 120.52M | 115.61M | 107.51M | 101.01M | 97.64M | 95.76M | 79.93M | 71.92M | 71.75M | 69.62M | 68.99M | 68.42M | 68.42M | 60.75M | 47.99M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $107.75M | $174.56M | $280.71M | $177.95M | $255.09M |
| Short Term Investments | $26.87M | $34.52M | $151.83M | $- | $- |
| Cash and Short Term Investments | $134.62M | $209.08M | $280.71M | $177.95M | $255.09M |
| Net Receivables | $- | $- | $30.00M | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.28M | $4.97M | $8.51M | $21.90M | $3.49M |
| Total Current Assets | $136.90M | $214.06M | $319.22M | $188.90M | $258.58M |
| Property Plant Equipment Net | $6.78M | $11.53M | $14.46M | $14.86M | $12.67M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $478.00K | $478.00K | $321 |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $978.00K | $478.00K | $183.00K | $1.88M | $2.15M |
| Total Non-Current Assets | $7.76M | $12.00M | $15.12M | $17.21M | $14.82M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $144.66M | $226.06M | $334.34M | $206.11M | $273.40M |
| Account Payables | $4.33M | $7.32M | $13.95M | $12.32M | $8.34M |
| Short Term Debt | $12.50M | $5.48M | $3.04M | $2.54M | $1.53M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $22.17M | $28.15M | $30.61M | $3.94M | $3.99M |
| Other Current Liabilities | $23.46M | $22.69M | $44.17M | $28.95M | $16.24M |
| Total Current Liabilities | $62.46M | $63.64M | $91.53M | $47.52M | $30.00M |
| Long Term Debt | $10.95M | $28.35M | $33.50M | $35.87M | $15.13M |
| Deferred Revenue Non-Current | $- | $97.17M | $117.04M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $80.76M | $1.00K | $203.00K | $974.00K | $174.00K |
| Total Non-Current Liabilities | $91.71M | $125.52M | $150.75M | $36.85M | $15.31M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $154.17M | $189.16M | $242.28M | $84.37M | $45.31M |
| Preferred Stock | $- | $- | $- | $- | $0 |
| Common Stock | $12.00K | $12.00K | $11.00K | $7.00K | $7.00K |
| Retained Earnings | $-895.55M | $-826.36M | $-654.69M | $-450.48M | $-280.42M |
| Accumulated Other Comprehensive Income Loss | $10.00K | $11.00K | $-152.00K | $- | $-0 |
| Other Total Stockholders Equity | $886.02M | $863.24M | $746.89M | $572.21M | $508.50M |
| Total Stockholders Equity | $-9.51M | $36.90M | $92.06M | $121.74M | $228.09M |
| Total Equity | $-9.51M | $36.90M | $92.06M | $121.74M | $228.09M |
| Total Liabilities and Stockholders Equity | $144.66M | $226.06M | $334.34M | $206.11M | $273.40M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $144.66M | $226.06M | $334.34M | $206.11M | $273.40M |
| Total Investments | $26.87M | $34.52M | $151.83M | $478.00K | $321 |
| Total Debt | $28.60M | $33.83M | $36.30M | $38.18M | $16.57M |
| Net Debt | $-79.15M | $-140.73M | $-244.41M | $-139.77M | $-238.52M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $107.75M | $78.87M | $59.00M | $75.19M | $174.56M | $186.28M | $286.59M | $122.83M | $280.71M | $290.13M | $135.34M | $230.06M | $177.95M | $191.71M | $227.39M | $228.43M | $255.09M | $270.94M | $288.38M | $60.45M |
| Short Term Investments | $26.87M | $76.30M | $103.74M | $107.96M | $34.52M | $54.70M | $157.86M | $151.09M | $151.83M | $106.04M | $89.79M | $- | $- | $- | $- | $- | $- | $- | $3.00M | $17.98M |
| Cash and Short Term Investments | $134.62M | $155.17M | $162.74M | $183.15M | $209.08M | $240.99M | $286.59M | $273.92M | $280.71M | $290.13M | $225.13M | $230.06M | $177.95M | $191.71M | $227.39M | $228.43M | $255.09M | $270.94M | $291.38M | $78.43M |
| Net Receivables | $- | $1.00M | $1.57M | $- | $- | $- | $- | $- | $30.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.00M | $-11.99M |
| Other Current Assets | $2.28M | $4.39M | $4.65M | $4.39M | $4.97M | $8.75M | $10.50M | $7.89M | $8.51M | $9.91M | $23.90M | $22.83M | $21.90M | $15.30M | $12.09M | $7.04M | $3.49M | $8.00M | $7.05M | $3.73M |
| Total Current Assets | $136.90M | $160.56M | $168.96M | $187.54M | $214.06M | $249.74M | $297.09M | $281.81M | $319.22M | $300.04M | $237.08M | $241.47M | $188.90M | $199.36M | $233.43M | $231.95M | $258.58M | $274.93M | $294.90M | $80.29M |
| Property Plant Equipment Net | $6.78M | $8.00M | $9.19M | $10.36M | $11.53M | $12.69M | $13.40M | $13.80M | $14.46M | $14.20M | $14.55M | $14.55M | $14.86M | $15.30M | $15.65M | $12.44M | $12.67M | $13.04M | $13.51M | $14.11M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $478.00K | $478.00K | $478.00K | $478.00K | $478.00K | $478.00K | $- | $478.00K | $478.00K | $478.00K | $478.00K | $478.00K | $321.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $978.00K | $978.00K | $978.00K | $-1 | $- | $- | $39.00K | $110.00K | $183.00K | $616.00K | $246.00K | $1.77M | $1.88M | $2.45M | $4.13M | $3.20M | $2.15M | $2.15M | $2.10M | $1.45M |
| Total Non-Current Assets | $7.76M | $8.97M | $10.16M | $10.83M | $12.00M | $13.17M | $13.91M | $14.39M | $15.12M | $14.81M | $15.27M | $16.80M | $17.21M | $18.23M | $20.25M | $15.96M | $14.82M | $15.19M | $15.61M | $15.57M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $144.66M | $169.53M | $179.13M | $198.37M | $226.06M | $262.90M | $311.00M | $296.19M | $334.34M | $314.85M | $252.35M | $258.27M | $206.11M | $217.59M | $253.69M | $247.91M | $273.40M | $290.13M | $310.52M | $95.86M |
| Account Payables | $4.33M | $2.03M | $3.01M | $3.09M | $7.32M | $12.95M | $16.92M | $18.16M | $13.95M | $13.73M | $8.16M | $9.78M | $12.32M | $5.87M | $10.65M | $11.74M | $8.34M | $4.53M | $7.16M | $4.60M |
| Short Term Debt | $16.36M | $15.21M | $15.64M | $8.76M | $5.48M | $6.27M | $6.05M | $5.81M | $3.04M | $5.39M | $5.18M | $4.81M | $2.54M | $4.47M | $4.52M | $3.14M | $1.53M | $1.37M | $2.79M | $2.32M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $22.17M | $31.37M | $29.34M | $25.62M | $28.15M | $21.59M | $20.50M | $28.77M | $30.61M | $30.92M | $26.23M | $16.58M | $3.94M | $3.96M | $3.97M | $3.98M | $3.99M | $4.00M | $4.01M | $4.80M |
| Other Current Liabilities | $19.60M | $19.68M | $14.19M | $15.95M | $22.69M | $27.12M | $31.45M | $30.67M | $44.17M | $38.74M | $31.90M | $25.30M | $28.95M | $29.73M | $21.34M | $16.06M | $16.24M | $11.26M | $8.46M | $5.77M |
| Total Current Liabilities | $62.46M | $68.30M | $62.18M | $53.41M | $63.64M | $67.93M | $74.92M | $83.40M | $91.53M | $88.79M | $71.47M | $56.46M | $47.52M | $44.02M | $40.47M | $34.92M | $30.00M | $21.07M | $22.42M | $17.49M |
| Long Term Debt | $12.24M | $16.29M | $20.32M | $24.32M | $28.35M | $31.20M | $32.01M | $32.78M | $33.50M | $34.14M | $34.84M | $35.27M | $35.87M | $16.98M | $17.41M | $14.74M | $15.13M | $15.55M | $14.30M | $15.03M |
| Deferred Revenue Non-Current | $79.46M | $- | $87.57M | $92.02M | $97.17M | $111.50M | $114.20M | $115.58M | $117.04M | $101.42M | $11.68M | $25.62M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $4.22M | $5.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $8.00K | $83.89M | $626.00K | $638.00K | $1.00K | $67.00K | $76.00K | $140.00K | $203.00K | $266.00K | $328.00K | $389.00K | $974.00K | $1.03M | $288.00K | $318.00K | $174.00K | $200.00K | $225.00K | $250.00K |
| Total Non-Current Liabilities | $91.71M | $100.18M | $108.52M | $116.98M | $125.52M | $142.78M | $146.28M | $148.50M | $150.75M | $135.83M | $46.85M | $61.28M | $36.85M | $18.02M | $17.70M | $15.05M | $15.31M | $15.75M | $14.53M | $15.28M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $154.17M | $168.48M | $170.70M | $170.39M | $189.16M | $210.71M | $221.20M | $231.90M | $242.28M | $224.62M | $118.32M | $117.74M | $84.37M | $62.04M | $58.17M | $49.97M | $45.31M | $36.82M | $36.95M | $32.77M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $2 | $- | $- | $- | $- | $- | $0 | $- | $- | $4.00K |
| Common Stock | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $11.00K | $11.00K | $10.00K | $10.00K | $9.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $7.00K | $5.00K |
| Retained Earnings | $-895.55M | $-881.44M | $-869.93M | $-845.67M | $-826.36M | $-806.82M | $-765.16M | $-710.85M | $-654.69M | $-609.77M | $-549.96M | $-497.74M | $-450.48M | $-401.50M | $-356.02M | $-315.11M | $-280.42M | $-251.57M | $-229.09M | $-209.30M |
| Accumulated Other Comprehensive Income Loss | $10.00K | $25.00K | $-71.00K | $-90.00K | $11.00K | $1.00K | $-49.00K | $12.00K | $-152.00K | $-231.00K | $-126.00K | $0 | $- | $- | $- | $- | $-0 | $- | $2.00K | $-4.00K |
| Other Total Stockholders Equity | $886.02M | $882.45M | $878.42M | $873.73M | $863.24M | $859.00M | $855.00M | $775.12M | $746.89M | $700.22M | $684.11M | $638.25M | $572.21M | $557.04M | $551.53M | $513.04M | $508.50M | $504.88M | $502.64M | $272.39M |
| Total Stockholders Equity | $-9.51M | $1.05M | $8.43M | $27.98M | $36.90M | $52.20M | $89.80M | $64.29M | $92.06M | $90.23M | $134.03M | $140.53M | $121.74M | $155.55M | $195.51M | $197.94M | $228.09M | $253.31M | $273.56M | $63.09M |
| Total Equity | $-9.51M | $1.05M | $8.43M | $27.98M | $36.90M | $52.20M | $89.80M | $64.29M | $92.06M | $90.23M | $134.03M | $140.53M | $121.74M | $155.55M | $195.51M | $197.94M | $228.09M | $253.31M | $273.56M | $63.09M |
| Total Liabilities and Stockholders Equity | $144.66M | $169.53M | $179.13M | $198.37M | $226.06M | $262.90M | $311.00M | $296.19M | $334.34M | $314.85M | $252.35M | $258.27M | $206.11M | $217.59M | $253.69M | $247.91M | $273.40M | $290.13M | $310.52M | $95.86M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $144.66M | $169.53M | $179.13M | $198.37M | $226.06M | $262.90M | $311.00M | $296.19M | $334.34M | $314.85M | $252.35M | $258.27M | $206.11M | $217.59M | $253.69M | $247.91M | $273.40M | $290.13M | $310.52M | $95.86M |
| Total Investments | $26.87M | $76.30M | $103.74M | $108.44M | $35.00M | $54.70M | $157.86M | $151.09M | $151.83M | $106.04M | $89.79M | $478.00K | $478.00K | $478.00K | $478.00K | $321.00K | $- | $- | $3.00M | $17.98M |
| Total Debt | $28.60M | $31.50M | $32.31M | $33.08M | $33.83M | $34.34M | $35.03M | $35.68M | $36.30M | $36.84M | $37.43M | $37.67M | $38.18M | $19.22M | $19.76M | $16.31M | $16.57M | $16.83M | $17.10M | $17.34M |
| Net Debt | $-79.15M | $-47.36M | $-26.69M | $-42.11M | $-140.73M | $-151.94M | $-251.56M | $-87.14M | $-244.41M | $-253.28M | $-97.91M | $-192.38M | $-139.77M | $-172.49M | $-207.63M | $-212.12M | $-238.52M | $-254.11M | $-271.28M | $-43.11M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-69.19M | $-171.67M | $-204.21M | $-170.06M | $-88.05M |
| Depreciation and Amortization | $1.63M | $1.52M | $927.00K | $855.00K | $1.01M |
| Deferred Income Tax | $- | $- | $- | $- | $-86.00K |
| Stock Based Compensation | $16.46M | $21.14M | $21.52M | $18.41M | $7.17M |
| Change in Working Capital | $-30.74M | $-18.76M | $133.10M | $10.09M | $5.11M |
| Accounts Receivables | $- | $30.00M | $-30.00M | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.86M | $-6.08M | $947.00K | $483.00K | $942.00K |
| Other Working Capital | $-27.88M | $-42.68M | $162.15M | $9.60M | $4.16M |
| Other Non Cash Items | $-496.00K | $-1.10M | $-699.00K | $723.00K | $148.00K |
| Net Cash Provided by Operating Activities | $-82.34M | $-168.88M | $-49.36M | $-139.99M | $-74.70M |
| Investments in Property Plant and Equipment | $-132.00K | $-2.17M | $-2.20M | $-648.00K | $-473.00K |
| Acquisitions Net | $- | $- | $150.52M | $- | $- |
| Purchases of Investments | $-133.43M | $-155.92M | $-247.52M | $- | $- |
| Sales Maturities of Investments | $145.00M | $277.97M | $97.00M | $- | $37.50M |
| Other Investing Activities | $- | $- | $-150.52M | $- | $37.50M |
| Net Cash Used for Investing Activities | $11.44M | $119.88M | $-152.72M | $-648.00K | $37.03M |
| Debt Repayment | $-2.23M | $-262.00K | $-272.00K | $18.34M | $-116.00K |
| Common Stock Issued | $5.78M | $93.54M | $150.89M | $43.09M | $227.03M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $542.00K | $1.40M | $2.40M | $2.22M | $3.50M |
| Net Cash Used Provided by Financing Activities | $4.09M | $94.67M | $153.02M | $63.65M | $230.41M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-66.81M | $45.68M | $-49.06M | $-76.99M | $192.74M |
| Cash at End of Period | $108.23M | $175.04M | $129.36M | $178.43M | $255.41M |
| Cash at Beginning of Period | $175.04M | $129.36M | $178.43M | $255.41M | $62.67M |
| Operating Cash Flow | $-82.34M | $-168.88M | $-49.36M | $-139.99M | $-74.70M |
| Capital Expenditure | $-132.00K | $-2.17M | $-2.20M | $-648.00K | $-473.00K |
| Free Cash Flow | $-82.47M | $-171.05M | $-51.56M | $-140.64M | $-75.17M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-14.12M | $-11.50M | $-24.27M | $-19.31M | $-19.54M | $-41.66M | $-54.31M | $-56.16M | $-44.92M | $-59.81M | $-52.22M | $-47.26M | $-48.98M | $-45.47M | $-40.91M | $-34.69M | $-28.84M | $-22.49M | $-19.79M | $-16.93M |
| Depreciation and Amortization | $400.00K | $-2.93M | $403.00K | $423.00K | $447.00K | $427.00K | $324.00K | $319.00K | $282.00K | $213.00K | $227.00K | $205.00K | $211.00K | $212.00K | $206.00K | $226.00K | $260.00K | $256.00K | $246.00K | $248.00K |
| Deferred Income Tax | $- | $- | $- | $- | $2.83M | $-1.05M | $-1.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-20.00K | $-66.00K |
| Stock Based Compensation | $3.35M | $4.03M | $4.42M | $4.66M | $4.08M | $4.00M | $6.64M | $6.41M | $5.31M | $5.38M | $5.35M | $5.49M | $4.86M | $4.93M | $4.58M | $4.04M | $1.99M | $1.92M | $1.66M | $1.61M |
| Change in Working Capital | $-9.19M | $1.22M | $-1.98M | $-18.13M | $-21.74M | $-8.02M | $-12.88M | $21.69M | $-11.02M | $108.92M | $1.78M | $33.42M | $908.00K | $4.19M | $1.62M | $3.37M | $9.24M | $85.00K | $1.93M | $-6.15M |
| Accounts Receivables | $1.00M | $570.00K | $- | $- | $- | $- | $- | $30.00M | $-30.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $2.30M | $-980.00K | $-8.00K | $-4.17M | $-5.42M | $-4.00M | $-1.39M | $4.73M | $-206.00K | $5.54M | $-1.86M | $-2.52M | $2.91M | $-4.70M | $-1.15M | $3.42M | $3.71M | $-2.39M | $2.32M | $-2.69M |
| Other Working Capital | $-12.48M | $1.63M | $-1.97M | $-13.97M | $-16.32M | $-4.03M | $-11.49M | $-13.04M | $19.18M | $94.43M | $-4.28M | $35.94M | $-2.00M | $8.89M | $2.76M | $-47.00K | $5.53M | $2.47M | $-384.00K | $-3.46M |
| Other Non Cash Items | $307.00K | $610.00K | $-435.00K | $9.37M | $-227.00K | $217.00K | $167.00K | $-1.26M | $-877.00K | $193.00K | $187.00K | $194.00K | $604.00K | $42.00K | $39.00K | $38.00K | $38.00K | $36.00K | $37.00K | $37.00K |
| Net Cash Provided by Operating Activities | $-19.25M | $-8.58M | $-21.86M | $-32.66M | $-34.15M | $-46.08M | $-61.83M | $-29.00M | $-51.23M | $54.60M | $-44.78M | $-7.96M | $-42.40M | $-36.10M | $-34.47M | $-27.02M | $-17.32M | $-20.20M | $-15.94M | $-21.25M |
| Investments in Property Plant and Equipment | $- | $- | $- | $-132.00K | $-386.00K | $-472.00K | $-399.00K | $-911.00K | $-785.00K | $-426.00K | $-657.00K | $-329.00K | $-155.00K | $-46.00K | $-333.00K | $-114.00K | $-188.00K | $-195.00K | $-25.00K | $-65.00K |
| Acquisitions Net | $- | $- | $- | $- | $101.52M | $-104.25M | $5.04M | $-2.31M | $54.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-26.53M | $-19.49M | $-87.42M | $-24.47M | $-9.72M | $-58.04M | $-63.69M | $-87.64M | $-70.06M | $-89.81M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $50.00M | $55.00M | $25.00M | $15.00M | $45.00M | $113.97M | $53.00M | $66.00M | $43.00M | $- | $- | $- | $- | $- | $- | $- | $-37.50M | $3.00M | $15.00M | $19.50M |
| Other Investing Activities | $- | $- | $- | $-72.42M | $-101.52M | $104.25M | $-5.04M | $2.31M | $-54.00M | $-16.07M | $-89.81M | $- | $- | $- | $- | $- | $37.50M | $3.00M | $15.00M | $19.50M |
| Net Cash Used for Investing Activities | $50.00M | $28.47M | $5.51M | $-72.55M | $20.15M | $103.78M | $-5.44M | $1.40M | $-45.43M | $-16.49M | $-90.47M | $-329.00K | $-155.00K | $-46.00K | $-333.00K | $-114.00K | $-188.00K | $2.81M | $14.97M | $19.43M |
| Debt Repayment | $-2.10M | $-23.00K | $-47.00K | $-65.00K | $-66.00K | $-65.00K | $-66.00K | $21.52M | $-65.00K | $-65.00K | $-66.00K | $-76.00K | $18.48M | $-65.00K | $-41.00K | $-33.00K | $62.81M | $-46.00K | $-29.00K | $-209.00K |
| Common Stock Issued | $- | $-5.52M | $-66.00K | $5.85M | $158.00K | $-81.00K | $71.89M | $21.73M | $39.94M | $10.59M | $39.99M | $60.37M | $9.80M | $-51.00K | $33.34M | $764.00K | $63.04M | $62.81M | $164.16M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $1.20M | $-81.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-259.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-227.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $228.00K | $- | $200.00K | $48.00K | $158.00K | $- | $1.36M | $-21.70M | $1.58M | $110.00K | $606.00K | $96.00K | $515.00K | $528.00K | $619.00K | $505.00K | $-124.18M | $-62.81M | $64.76M | $119.00K |
| Net Cash Used Provided by Financing Activities | $-1.87M | $-23.00K | $153.00K | $5.83M | $92.00K | $-146.00K | $73.18M | $21.55M | $41.46M | $10.64M | $40.53M | $60.39M | $28.80M | $463.00K | $33.92M | $472.00K | $1.67M | $-49.00K | $228.89M | $-90.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $28.88M | $19.87M | $-16.19M | $-99.38M | $-11.72M | $57.55M | $5.91M | $-6.06M | $-55.20M | $48.74M | $-94.72M | $52.11M | $-13.76M | $-35.68M | $-885.00K | $-26.66M | $-15.84M | $-17.44M | $227.93M | $-1.90M |
| Cash at End of Period | $108.23M | $79.35M | $59.00M | $75.19M | $174.56M | $186.76M | $129.21M | $123.30M | $129.36M | $184.56M | $135.82M | $230.53M | $178.43M | $192.19M | $227.87M | $228.75M | $255.41M | $271.26M | $288.70M | $60.77M |
| Cash at Beginning of Period | $79.35M | $59.48M | $75.19M | $174.56M | $186.28M | $129.21M | $123.30M | $129.36M | $184.56M | $135.82M | $230.53M | $178.43M | $192.19M | $227.87M | $228.75M | $255.41M | $271.26M | $288.70M | $60.77M | $62.67M |
| Operating Cash Flow | $-19.25M | $-8.58M | $-21.86M | $-32.66M | $-34.15M | $-46.08M | $-61.83M | $-29.00M | $-51.23M | $54.60M | $-44.78M | $-7.96M | $-42.40M | $-36.10M | $-34.47M | $-27.02M | $-17.32M | $-20.20M | $-15.94M | $-21.25M |
| Capital Expenditure | $- | $- | $- | $-132.00K | $-386.00K | $-472.00K | $-399.00K | $-911.00K | $-785.00K | $-426.00K | $-657.00K | $-329.00K | $-155.00K | $-46.00K | $-333.00K | $-114.00K | $-188.00K | $-195.00K | $-25.00K | $-65.00K |
| Free Cash Flow | $-19.25M | $-8.58M | $-21.86M | $-32.79M | $-34.53M | $-46.55M | $-62.23M | $-29.92M | $-52.01M | $54.17M | $-45.43M | $-8.28M | $-42.55M | $-36.14M | $-34.80M | $-27.14M | $-17.51M | $-20.39M | $-15.96M | $-21.31M |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
$0.43
Stock Price
$53.95M
Market Cap
102
Employees
Cambridge, MA
Location
Revenue (FY 2024)
$40.50M
9.9% YoY
Net Income (FY 2024)
$-69.19M
59.7% YoY
EPS (FY 2024)
$-0.56
62.2% YoY
Free Cash Flow (FY 2024)
$-82.47M
51.8% YoY
Profitability
Gross Margin
96.0%
Net Margin
-170.9%
ROE
727.6%
ROA
-47.8%
Valuation
P/E Ratio
-2.53
P/S Ratio
4.33
EV/EBITDA
-1.52
Market Cap
$53.95M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-82.34M
51.2% YoY
Free Cash Flow
$-82.47M
51.8% YoY
Balance Sheet Summary
Total Assets
$144.66M
-36.0% YoY
Total Debt
$28.60M
15.5% YoY
Shareholder Equity
$-9.51M
-124.4% YoY
Dividend Overview
No Dividend Data
Mersana Therapeutics, Inc. doesn't currently pay dividends.
Mersana Therapeutics Dividends
Explore Mersana Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Mersana Therapeutics News
Read the latest news about Mersana Therapeutics, including recent articles, headlines, and updates.
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the following presentations related to emiltatug ledadotin (Emi-Le; XMT-1660), Mersana's B7-H4-directed Dolasynthen ADC, will be given at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30-June 3, 2025 at McCormick Place, Chicago, IL:
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2025, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 26,790 shares of its common stock, to one new employee whose employment commenced in March 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Phase 1 dose escalation and backfill cohort clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) will be presented in an oral session at the ESMO Breast Cancer 2025 Annual Congress, which is being held from May 14-17, 2025, in Munich, Germany.
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024.
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types - First expansion cohort initiated in patients with TNBC previously treated with at least one topo-1 ADC; dose exploration efforts ongoing - Company announces expected 2025 milestones and areas of focus - Conference call today at 8:30 a.m. ET
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 quarters excluding collaboration revenues. The promise of phase 1 trial data gives us a chance to see if Mersana's ADC platform can make drugs that are more tolerable than those being developed by competitors.
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO & COO Conference Call Participants Tara Bancroft - TD Cowen Yen-Der Li - Leerink Partners Charles Zhu - LifeSci Capital Ashiq Mubarack - Citi Yige Guo - Guggenheim Justin Zelin - BTIG Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2024.
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communications Martin Huber - President & Chief Executive Officer Brian DeSchuytner - Chief Financial Officer & Chief Operating Officer Conference Call Participants Tara Bancroft - TD Cowen Kaveri Pohlman - BTIG Dylan Drakes - Leerink Partners Brian Cheng - JPMorgan Michael Schmidt - Guggenheim Asthika Goonewardene - Truist Ashiq Mubarack - Citi Colleen Kusy - Baird Operator Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all participants are in listen-only mode.
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in April 2024. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MRSN.